Digest Network Come funziona
Network
/
Società
On
Non verificato

Ono Pharmaceutical Co., Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

9 comunicati stampa

Guarda tutti i comunicati
15/01/2026
Scienza
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Web e Social Network
Eventi
Ono Shares Replay Information for 44th Annual J.P. Morgan Healthcare Conference Presentation
Fonte
Ono Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
12/01/2026
Eventi
Web e Social Network
Scienza
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Ono to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Ono Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
09/10/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
Ono Announces ONO-4578 (EP4 antagonist) in Combination with Opdivo and Chemotherapy Met the Primary Endpoint in a Phase 2 Clinical Trial in Patients with Certain Gastric Cancer
Fonte
Ono Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
09/10/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Ono Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy
Fonte
Ono Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
23/06/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Mercato del lavoro
Industria
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
Fonte
Ono Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
28/05/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
ONO PHARMA Presents Positive Results From Pivotal Trial in U.S. Patients With Relapsed or Refractory PCNSL at 2025 ASCO Annual Meeting
Fonte
Ono Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
24/04/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting
Fonte
Ono Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
21/04/2025
Industria
Scienza
Tecnica
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Oncologia
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
Fonte
Ono Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0
11/03/2025
Mercato del lavoro
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
Fonte
Ono Pharmaceutical Co., Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0